SIMULTANEOUS ANALYTICAL METHOD DEVELOPMENT OF 6-MERCAPTOPURINE AND 6-METHYLMERCAPTOPURINE IN DRIED BLOOD SPOT USING ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY
Objective: 6-mercaptopurine (6-MP) is a chemotherapeutic agent in the antimetabolite class. It has to go through the metabolic pathway to form
6-methyl MP (6-MMP). This study aimed to obtain an optimum and validated method for the analysis of 6-MP and 6-MMP in dried blood spot (DBS)
samples simultaneously and to evaluate the potential for future drug concentration monitoring in DBS samples.
Methods: The quality control and calibration curves were made by spotting 40 Î¼L blood on DBS paper and dried for 3 hrs. DBS papers were cut with a
diameter of 8 mm and extracted with acetonitrile-methanol (1:3) containing internal standard 5-fluorouracil (5-FU). Separation was performed with
waters acquity ultra performance liquid chromatography BEH C18 column of 1.7 Î¼m (2.1Ã—100 mm) with a mobile phase consisting of 0.1% formic
acid in water 0.1% formic acid in acetonitrile with gradient elution and a flow rate of 0.2 mL/minute. Mass detection was performed using Waters
Xevo TQD with positive electrospray ionization (ESI) for 6-MP and 6-MMP and negative ESI for 5-FU in the multiple reaction monitoring mode.
Results: The detection rates of 6-MP, 6-MMP, and 5-FU were 153.09>119.09, 167.17>126.03, and 129.09>42.05, respectively. This method was linear
with the range at 26-1000 ng/mL for 6-MP and 13-500 ng/mL for 6-MMP with consecutive râ‰¥0.998 and â‰¥0.999, respectively. The % relative error
value and % relative standard deviation for accuracy and precision of intraday and interday were not more than 15% and not more than 20% at the
lower limit of quantification concentration, respectively.
Conclusions: This method fulfilled the requirements of selectivity, linearity, carry over, and matrix effects referring to the European Medicines Agency
2. Beaumais TA, Fakhoury M, Medard Y, Azougagh S, Zhang D,
Yakouben K, et al. Determinants of mercaptopurine toxicity in
paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin
3. Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine/
Methotrexate maintenance therapy of childhood acute lymphoblastic
leukemia: Clinical facts and fiction. J Pediatr Hematol Oncol
4. Schmiegelow K, Bretton-Meyer U 6-mercaptopurine dosage and
pharmacokinetics influence the degree of bone marrow toxicity
following high-dose methotrexate in children with acute lymphoblastic
leukemia. Leukemia 2001;15(1):74-9.
5. Kirchherr H, Shipkova M, von Ahsen N. Improved method for
therapeutic drug monitoring of 6-thioguanine nucleotides and
6-methylmercaptopurine in whole-blood by LC/MSMS using isotopelabeled
internal standards. Ther Drug Monit 2013;35(3):313-21.
6. DÃ©glon J, Thomas A, Mangin P, Staub C. Direct analysis of dried
blood spots coupled with mass spectrometry: Concepts and biomedical
applications. Anal Bioanal Chem 2012;402(8):2485-98.
7. Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring
by dried blood spot: Progress to date and future directions. Clin
8. Evans C, Arnold M, Bryan P, Duggan J, James CA, Li W, et al.
Implementing dried blood spot sampling for clinical pharmacokinetic
determinations: Considerations from the IQ consortium microsampling
working group. AAPS J 2015;17(2):292-300.
9. Hawwa AF, Al Bawab A, Rooney M, Wedderburn LR, Beresford MW,
McElnay JC. A novel dried blood spot-LCMS method for the
quantification of methotrexate polyglutamates as a potential marker for
methotrexate use in children. PLOS One 2014;9(2):e89908.